Long Shortz with Optiscan Imaging: Getting a clear snapshot in breast cancer surgery study

Optiscan Imaging’s managing director and CEO Dr Camile Farah joins Sarah Hughan on Stockhead TV to talk about its InVue imaging platform.

Stockhead’s Sarah Hughan sits down with Optiscan (ASX:OIL)  CEO and managing director Dr Camile Farah to get the short end of the long story on the company’s latest news.

The med-tech company has received ethical clearance to undertake a human study of cancer margins in patients presenting for surgical treatment of breast cancer.

The study will assess its InVue precision surgery imaging platform during surgery to collect imaging data of the surgical cavity after tumour removal.

Tune in to hear Optiscan's Dr Camile Farah on how InVue works, the breast cancer study, and more.

This video was developed in collaboration with Optiscan, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Optiscan Imaging: Getting a clear snapshot in breast cancer surgery study